Created by potrace 1.16, written by Peter Selinger 2001-2019beatandraise.com
Latest FinancialsFinancialsexperimental

Filings:

CategoryDateSearch FilingsInstitutional HoldersbetaEarnings TranscriptsbetaGlobal Search

SEC Edgar

BRISTOL MYERS SQUIBB CO

Support
aboutterms

Financialsexperimental

BRISTOL MYERS SQUIBB CO (CELG-RI). Every figure is as filed in the company's 10-Q and 10-K reports. Quarters a filing does not report on their own are worked out from its year-to-date figures and marked *.

Income StatementBalance SheetCash FlowQuarterlyAnnual

USD in millions

Cash Flow
Q2 FY26
30 Jun 2026
Q1 FY26
31 Mar 2026
Q4 FY25
31 Dec 2025
Q3 FY25
30 Sept 2025
Q2 FY25
30 Jun 2025
Q1 FY25
31 Mar 2025
Q4 FY24
31 Dec 2024
Q3 FY24
30 Sept 2024
Q2 FY24
30 Jun 2024
Q1 FY24
31 Mar 2024
Q4 FY23
31 Dec 2023
Q3 FY23
30 Sept 2023
Q2 FY23
30 Jun 2023
Q1 FY23
31 Mar 2023
Q4 FY22
31 Dec 2022
Q3 FY22
30 Sept 2022
Q2 FY22
30 Jun 2022
Q1 FY22
31 Mar 2022
Q4 FY21
31 Dec 2021
Net earnings/(loss)3,316*2,6781,085*2,195*1,313*2,46276*1,215*1,684*-11,9081,762*1,934*2,077*2,2672,025*1,608*1,429*1,2832,372*
Depreciation and amortization, net594*594977*1,011*1,011*1,0121,880*2,592*2,596*2,5322,464*2,435*2,432*2,4292,521*2,588*2,583*2,5842,579*
Deferred income taxes-195*161-392*-359*-437*223-791*-256*-331*-711-1,327*-327*-1,086*-548-624*-645*-782*-687-1,266*
Stock-based compensation135*146133*139*137*144120*129*125*133127*132*137*122119*115*116*107133*
Impairment charges422*412584*196*1,953*139*870*129*159*47*2035*61*42*4115*
Divestiture gains and royalties-295*-293*-292-288*-270*-280-222*-223*-194-208*-225*-387-222*
Pension settlements and amortization75*
Divestiture gains and royalties-142*-34
Acquired IPRD86*
Acquired IPRD0*941,393*633*1,507*18830*262*132*12,949600*80*158*7530*400*333
Equity investment (gains)/losses-12*-107*-102-0*58*15514*308*644
Equity investment (gains)/losses, net-114*-134-190*-190*22*78
Contingent consideration fair value adjustments15*0*-10*0*0*1-32*
Other adjustments1*21308*-74*-12*10-29*103*-2*2248*269*-13*454*-40*-30*248-26*
Receivables-1,183*1,68719*155*-484*15143*661*-1,019*479-508*-247*-65*-175-106*-674*-669*786-168*
Inventories-36*1471*-90*4*-169175*-218*-225*-218-197*-256*-16*-282-41*-16*-13*1-128*
Accounts payable-29*409-90*160*13*-85517*-374*-259*300444*-268*-165*187405*-300*-19*23226*
Rebates and discounts360*-3,495-2,398*1,703*881*-627-405*1,819*735*-665-211*1,533*492*-910-303*1,140*520*-930
Income taxes payable-522*187-324*887*-621*54121*-348*-1,943*9101,044*-412*-2,119*884-1,113*60*-1,201*831-222*
Other786*-1,6361,068*240*222*-1,059725*167*340*-608283*-59*173*-1,064700*-46*-191*-1,073-627*
Net cash provided by operating activities3,393*1,1041,974*6,311*3,917*1,9544,439*5,591*2,326*2,8344,252*4,751*1,887*2,9703,306*3,687*2,261*3,8124,057*
Sale and maturities of marketable debt securities605*359402*829*524*22062*238*75*74741*365*270*571,206*1,417*1,688*2,1001,244*
Purchase of marketable debt securities-2,070*-781-78*-665*-621*-636-371*-40*-84*-274-717*-502*-355*-200-26*-274*-1,578*-1,714-2,070*
Proceeds from sales of equity investments38*39116*49*0*12205*0*55*50*148*5*6263*148*2
Capital expenditures-305*-347-370*-320*-361*-260-378*-324*-262*-284-330*-342*-259*-278-346*-247*-272*-253-320*
Divestiture and other proceeds279*270*243255*270*241247*194*227221*192*402178*
Divestiture and other proceeds209*312
Acquisition and other payments, net of cash acquired-91*-65-1,707*-1,874*-285*-78-47*-348*-1,373*-20,053-581*-326*-184*-78-116*-3,261*-467*-442-152*
Net cash provided by/(used in) investing activities-1,614*-131-1,458*-1,702*-473*-499-196*-219*-1,319*-19,618-1,346*-410*-329*-2101,213*-2,081*-289*95401*
Short-term debt obligations, net3,070-353*-10*115*128136*-72*88*42-114*
Proceeds from issuance of short-term debt obligations0*0*0*00*0*
Other short-term financing obligations, net-130*321-406*5*58*368-405*95*
Repayments of long-term debt-1,220*-500-10,068*-229*-0*-2,478*-395*-0-2,000*-0*-239*-1,640-0*-2,785*-2,877*-5,769-0*
Repayments of short-term debt obligations0*0*0*269*
Dividends-1,287*-1,283-1,262*-1,263*-1,262*-1,258-1,218*-1,216*-1,217*-1,212-1,160*-1,191*-1,197*-1,196-1,145*-1,154*-1,150*-1,185-1,099*
Proceeds from issuance of long-term debt0*0*12,8830*0*00*0*5,926
Stock option proceeds and other, net7*-98-33*-3*11*-103-19*16*-6*-9741*53*-92
Proceeds from issuance of long-term debt5,740*0*0*0
Net cash provided by/(used in) financing activities-2,630*-1,560-6,029*-1,490*-1,836*-993-1,642*-3,852*-4,023*14,644967*-5,160*-2,173*-3,050-3,246*-4,543*-3,520*-5,653-3,967*
Effect of exchange rates on cash, cash equivalents and restricted cash-10*-485*-4*128*66-147*77*-22*-4578*-38*-8*1395*-66*-71*9-54*
Repurchase of common stock0*0*0*00*4,000*905*2502,416*585*0*5,0002,751*
Stock option proceeds and other, net179*53*419*333-3*
Increase/(decrease) in cash, cash equivalents and restricted cash-861*-635-5,508*3,115*1,736*5282,454*1,597*-3,038*-2,1853,951*-857*-623*-2771,368*-3,003*-1,619*-1,737437*
Cash, cash equivalents and restricted cash at beginning of period9,583*10,21815,726*12,611*10,875*10,3477,893*6,296*9,334*11,5197,568*8,425*9,048*9,3257,957*10,960*12,579*14,31613,879*
Cash, cash equivalents and restricted cash at end of period8,7229,58310,21815,72612,61110,87510,3477,8936,2969,33411,5197,5688,4259,0489,3257,95710,96012,57914,316